TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy

被引：7

作者：

Alberto Henriquez-Hernandez, Luis ^{[1
]}

Fernandez Perez, Leandro ^{[1
]}

Gonzalez Hernandez, Ana ^{[2
]}

Cabrera de Leon, Antonio ^{[2
]}

Diaz-Chico, Bonifacio ^{[3
]}

Murias Rosales, A. ^{[4
]}

机构：

[1] Univ Las Palmas Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria 35016, Spain

[2] Hosp Univ La Candelaria, Hosp La Candelaria, Res Unit, Santa Cruz de Tenerife 38010, Spain

[3] Univ Las Palmas Gran Canaria, Physiol Biochem & Mol Biol Dept, Las Palmas Gran Canaria 35016, Spain

[4] Hosp Univ Insular Gran Canaria, Med Oncol Serv, Las Palmas Gran Canaria 35016, Spain

来源：

CANCER EPIDEMIOLOGY | 2010年 / 34卷 / 04期

关键词：

Breast cancer; Adjuvant chemotherapy; Multifocal tumour; Polymorphism; PCR-RFLP; Risk factors; MTHFR; THYMIDYLATE SYNTHASE GENE; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK; FOLATE; DISEASE; METABOLISM; EXPRESSION; GENOTYPE; C3435T; DIET;

D O I：

10.1016/j.canep.2010.03.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose. The distribution of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms was investigated in 80 consecutive breast cancer patients treated with adjuvant chemotherapy Results Observed allelic frequencies were TSER, (2)0 55 and (3)0 45, MTHFR C677T, (C) 065 and (T) 035: p53 Arg72Pro, (Arg) 076 and (Pro) 024, MDR1 C3435T, (C) 051 and (T) 0.49 MTHFR C677T was found to be a strong predictor of the presence of multifocal tumour (odds ratio, 4 1, 95% CI, 1 1-15 7, P = 0 035) Conclusion Our data indicate that breast cancer patients with the C/C variant may Present multifocal tumour most frequently (C) 2010 Elsevier Ltd All rights reserved

引用

下载

页码：490 / 493

页数：4

共 50 条

[41] Investigation on MDR1 gene polymorphisms and its relationship with breast cancer risk factors in Chinese women
Fang, Yi
Zhao, Qingyu
Ma, Gang
Han, Yujing
Lou, Ning
MEDICAL ONCOLOGY, 2013, 30 (01)
[42] Investigation on MDR1 gene polymorphisms and its relationship with breast cancer risk factors in Chinese women
Yi Fang
Qingyu Zhao
Gang Ma
Yujing Han
Ning Lou
Medical Oncology, 2013, 30
[43] Waf-1 (p21) and p53 polymorphisms in breast cancer
Keshava, C
Frye, BL
Wolff, MS
McCanlies, EC
Weston, A
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (01) : 127 - 130
[44] PHARMACOGENETICS OF TAMOXIFEN ADJUVANT THERAPY AND ITS EFFICIACY: MDR1 POLYMORPHISMS IN CYP2D6 EXTENSIVE METABOLIZERS WITH BREAST CANCER
Csov, S. Argal
Slanar, O.
Bakhouche, H.
Drazdakova, M.
Matouskova, O.
Zima, T.
Pertuzelka, L.
ANNALS OF ONCOLOGY, 2012, 23 : 81 - 81
[45] MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine
Drescher, S
Schaeffeler, E
Hitzl, M
Hofmann, U
Schwab, M
Brinkmann, U
Eichelbaum, M
Fromm, MF
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (05) : 526 - 534
[46] p53 autoantibodies in sera of breast cancer patients: Association with p53 gene mutations and p53 protein overexpression.
Angelopoulou, K
Yu, H
Diamandis, EP
CLINICAL CHEMISTRY, 1997, 43 : 770 - 770
[47] MDR1 gene polymorphisms and P-glycoprotein expression in respiratory diseases
Milojkovic, Maja
Milacic, Nena
Radovic, Jelena
Ljubisavljevic, Srdjan
BIOMEDICAL PAPERS-OLOMOUC, 2015, 159 (03): : 341 - 346
[48] p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer
Angelopoulou, K
Yu, H
Bharaj, B
Giai, M
Diamandis, EP
CLINICAL BIOCHEMISTRY, 2000, 33 (01) : 53 - 62
[49] Effect of MDR1 Gene Polymorphisms and Haplotypes on Taxanes-Based Chemotherapy Responses in Chinese Han Patients with Breast Cancer
Tang, J.
Zhao, J.
Wang, J.
Qin, J.
Xu, B.
CANCER RESEARCH, 2010, 70
[50] p53: Prospects for cancer gene therapy
Soddu, S
Sacchi, A
CYTOKINES CELLULAR & MOLECULAR THERAPY, 1998, 4 (03) : 177 - 185

← 1 2 3 4 5 →